Profitable companies and non-Profitable Biotech companies (rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012.
This trend continued in the next five years driven by launch of Innovative drugs catering to unmet needs in Alzheimer’s, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.
The early part of the previous decade (2010-20) was spent recovering from the big acquisitions made by this sector but followed by the exercising of some restrain for similar large acquisitions as investors wanted to see the returns reflected in the top-line and EPS. However in- licensing of early or mid stage compounds or small acquisitions continued since the Rising Stars kept throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases.
Patent expiry impact was also modest as majority had “not so easy to copy” biologics and other drugs in their portfolio. They, however were not complacent and were not leaving any stones unturned to meet the challenges as well as exploring emerging market opportunities with local partners. Favorable regulatory environment finally saw biosimilar mAbs entry in regulated markets The optimism of biosimilar players is reflected in the maturing pipeline. Para IV Filing from other generic players continues to pour leaving room for surprises and volatility.
Moving forward the sector should see a strategic rise of the digital mindset and further adoption of transformative and augumentative technologies. While mergers & acquisitions can still expect a sharper focus despite being more traditional, external innovation should result in a meaningful shift in culture through innovative and creative partnerships with both new entrants and less traditional companies.
There will be an increasing demand for even more transparency and disclosure and a need for real relationship-driven partnerships will encroach across all sector stakeholders including regulators, patients, advocacy groups and also to outsourcing players critical to the supply chain. Data will be a dominating force behind new revenue models and crucial to understanding and delivering an exceptional patient experience. Pricing will continue to exert much pressure, increasing access to drugs, growth of gene and cell therapies, and uncertain trade policies will further change the dynamics of the market.
Industry News
- New AI Tracks Children’s Tiny Movements Accuratelyby Bioengineer on October 14, 2025 at 6:25 am
In the intricate realm of environmental health science, quantifying the subtle, everyday behaviors of children—dubbed microactivities—remains a formidable challenge. These microactivities, particularly hand- and object-to-mouth contacts, significantly influence the extent of environmental exposure to harmful contaminants. Collecting accurate data on these behaviors has traditionally required painstaking manual annotation of pre-recorded videos, a process that is
- Exploring Touch Avoidance in Autism Spectrum Experiencesby Bioengineer on October 14, 2025 at 6:19 am
The intricate relationship between touch and social interaction has garnered significant focus in recent years, particularly in the context of autism spectrum disorders (ASD). A groundbreaking study led by Mello et al. in 2025 presents a compelling exploration of how touch avoidance centralizes experiences of social touch for individuals on the autism spectrum. This research
- Revolutionizing Molecular Design with ED2Mol Insightsby Bioengineer on October 14, 2025 at 6:16 am
In the rapidly evolving field of drug discovery, the integration of advanced computational techniques has begun to reshape the way researchers approach the identification and optimization of new therapeutic compounds. One of the most promising developments in this area is generative drug design, which uses algorithms to explore the vast chemical space available to scientists.
- Psychedelics Unveil Innovative Therapeutic Approaches for Stress-Related Psychiatric Disordersby Bioengineer on October 14, 2025 at 5:30 am
In a groundbreaking peer-reviewed viewpoint published this month in the journal Psychedelics, Professor Xiaohui Wang and colleagues present a comprehensive synthesis exploring the profound therapeutic potential of psychedelic substances in treating stress-related psychiatric disorders. This article meticulously examines emerging neurobiological mechanisms through which compounds such as psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) offer
- New Brain Cell Discoveries Revolutionize Understanding of Psychiatric Disordersby Bioengineer on October 14, 2025 at 5:29 am
In a groundbreaking interview published in the October 2025 issue of Genomic Psychiatry, Dr. Bruce M. Cohen, the Robertson-Steele Professor of Psychiatry at Harvard Medical School and Director of the Program for Neuropsychiatric Research at McLean Hospital, offers a transformative vision that could redefine the future of neuropsychiatric disorder research and treatment worldwide. With nearly
- Comprehensive Review Explores MDMA’s Role in PTSD Treatment and Emerging Psychiatric Applicationsby Bioengineer on October 14, 2025 at 5:25 am
A landmark review published in the October 2025 issue of Psychedelics delivers an unprecedented synthesis of the latest advances in MDMA-assisted psychotherapy, capturing the compound’s complex journey from its 1912 synthesis to the cutting-edge clinical applications reshaping psychiatric treatment. Spearheaded by Dr. Kenji Hashimoto and colleagues, this comprehensive analysis intricately weaves together neurobiological mechanisms, clinical
- Predicting AML Chemosensitivity with ARTN and CCL23by Bioengineer on October 14, 2025 at 5:19 am
In the field of oncology, one of the pressing challenges has always been predicting how patients will respond to chemotherapy. Researchers at the cutting edge of proteomics are actively working on unraveling the complexities surrounding this issue, particularly within the context of acute myeloid leukemia (AML). In a groundbreaking study described in the journal Clinical
- Immunity to Measles Reaches 90% in British Columbia’s Lower Mainlandby Bioengineer on October 14, 2025 at 4:49 am
In the densely populated Lower Mainland of British Columbia, a recent serological survey has revealed a strikingly high prevalence of measles antibodies among residents, underscoring the region’s robust immunization efforts. Published in the Canadian Medical Association Journal, this population-based, cross-sectional study conducted in August 2024 analyzed blood samples from over 1,000 individuals spanning multiple age
- 2024 NASEM Long COVID Definition: Research Foundationby Bioengineer on October 14, 2025 at 4:43 am
The impact of Long COVID has become an increasingly prominent topic within the realm of healthcare research, particularly as we strive to comprehend the long-term effects of SARS-CoV-2. In a groundbreaking study, Troxel, Krishnan, and Verduzco-Gutierrez lay the groundwork for a nuanced understanding of Long COVID with their paper titled “The 2024 NASEM Long COVID
- Preterm Neonatal Mortality: Urban vs. Rural Chinaby Bioengineer on October 14, 2025 at 4:37 am
In the rapidly modernizing landscapes of China, a new study has shed light on a critical, yet alarming issue: the urban-rural disparity in preterm neonatal mortality rates. Conducted by researchers Liu, Kang, and Zou, this extensive retrospective study compiles data that poignantly illustrates how geographic and socioeconomic factors contribute to the health outcomes of newborns
- Trained Immunity: The Inflammatory Memory in Diseaseby Bioengineer on October 14, 2025 at 4:31 am
In recent years, the concept of trained immunity has been revolutionizing our understanding of how the immune system adapts to threats in a manner previously thought to be exclusive to adaptive immunity. In a groundbreaking new study published in Cell Research in 2025, Schlüter, van Elsas, Priem, and colleagues delve deeply into the phenomenon of
- Silicon Ultrasound Patch Advances Eco-Friendliness While Boosting Performanceby Bioengineer on October 14, 2025 at 4:28 am
Researchers are continually pushing the boundaries of technological innovation in medical devices, particularly in the field of ultrasound imaging. Recently, an ambitious research team led by Dr. Byung Chul Lee from the Korea Institute of Science and Technology (KIST) has unveiled a significant advancement that promises to reshape how ultrasound devices are conceptualized and utilized.
- Study Finds Mom’s Voice Enhances Language-Center Development in Preemies’ Brainsby Bioengineer on October 14, 2025 at 4:19 am
Hearing Mother’s Voice Sparks Accelerated Language Pathway Development in Premature Infant Brain A groundbreaking study led by Stanford Medicine researchers has demonstrated that regular exposure to a mother’s voice can significantly enhance the development of critical language-processing pathways in the brains of premature infants. This novel intervention, involving recorded maternal speech played during the latter
- Revolutionizing Neural Networks with Lithium Niobate Technologyby Bioengineer on October 14, 2025 at 3:33 am
In an exciting breakthrough for the world of computing, researchers have unveiled a revolutionary approach that leverages the unique properties of nonlinear phononics, specifically on the versatile platform of lithium niobate. This pioneering work, centered on synthetic-domain computing, heralds a new era for analogue computing, promising to enhance the efficiency of arithmetic operations while tackling
- Advances in Molecular Biology for PMI Estimationby Bioengineer on October 14, 2025 at 3:24 am
In the realm of forensic medicine, accurately determining the post-mortem interval (PMI)—the time elapsed since death—remains a formidable challenge with profound implications for criminal investigations and legal proceedings. Recent advancements in molecular biology herald a transformative era in PMI estimation, offering unprecedented precision and reliability. The latest comprehensive review by He, Song, and Fu published
- Trust and Online Info: Impact on Cancer Careby Bioengineer on October 14, 2025 at 3:18 am
In recent years, the discourse surrounding patient-centered care has gained significant traction, particularly within the realm of oncology. A pivotal study conducted by Eskiler, Bilir, and Altunisik delves into the intricacies of patient-centered communication and its correlation with health outcomes among Turkish cancer patients undergoing chemotherapy. This research unveils compelling insights, highlighting the essential roles
- New Actinobacterium Discovered in Cyclosorus Parasiticus Soilby Bioengineer on October 14, 2025 at 3:06 am
Researchers have recently unveiled a novel actinobacterium strain designated as cg36^T, isolated from the rhizosphere of a plant species known as Cyclosorus parasiticus. This groundbreaking study presents a comprehensive polyphasic taxonomic investigation which not only identifies this new strain but also places it within a well-defined taxonomic framework. The rhizosphere, the region of soil that
- Enhanced CRISPR Diagnostics with Bead-Based Sensitivityby Bioengineer on October 14, 2025 at 3:00 am
Innovations in CRISPR diagnostics have ushered in a new era in disease detection and treatment, allowing for unprecedented sensitivity and multiplexing capabilities that revolutionize healthcare. The latest research conducted by Siddiqui, Welch, and Nguyen opens up intriguing avenues toward enhancing these groundbreaking diagnostic tools through bead-based technologies. Their study delves deep into the mechanics of
- Weekly Dish Swaps Boost Health and Sustainabilityby Bioengineer on October 14, 2025 at 2:54 am
In a significant breakthrough for both public health and environmental sustainability, recent research by Flynn et al. presents a compelling argument for the adoption of a “dish swap” approach to weekly meal planning. This innovative concept involves the strategic exchange of food items within weekly menus, thereby optimizing nutrient intake while simultaneously reducing ecological impacts.
- Nanoparticle Sensor Detects Calcium in Nasal Secretionsby Bioengineer on October 14, 2025 at 2:45 am
A groundbreaking study led by Imam, M.S. and collaborators, unveiled a nanoparticle-modified paper-based analytical sensor that promises to revolutionize the diagnosis of olfactory dysfunction and its possible correlation with specific calcium levels in human nasal secretions. This innovation merges the fields of nanotechnology and sensory health, offering a unique approach to a widely overlooked aspect
- Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangleby Willow Shah-Neville on October 13, 2025 at 1:00 pm
Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so special. The post Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangle appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- 'Not here to refine the status quo': Excellergy emerges with $70M, plans to redefine allergy therapeuticson October 13, 2025 at 10:11 am
The California biotech is developing a new drug class in hopes of redefining the standard of care for several allergic diseases.
- Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rateson October 13, 2025 at 9:10 am
Tvardi Therapeutics has failed its first big test as a public company. Months after joining Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in a phase 2 trial of its idiopathic pulmonary fibrosis prospect.
- Gilead, Arcus keep TIGIT dream alive with 27-month OS data from phase 2 cancer cohorton October 13, 2025 at 5:10 am
Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months, keeping alive one of the last remaining hopes for this once-hyped modality.
- Moderna posts melanoma data behind decision to say 'I do' to IDOon October 13, 2025 at 5:03 am
Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.
- Novo shutters cell therapy unit, ending work on potential Type 1 diabetes 'cure'on October 10, 2025 at 3:02 pm
Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the division’s 250 employees, according to a Danish publication.
- J&J in talks to buy immunology partner Protagonist: WSJon October 10, 2025 at 2:14 pm
Johnson & Johnson may be looking to deepen its relationship with immunology partner Protagonist Therapeutics with a takeover deal, The Wall Street Journal reports.
- Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next stepby Dylan Kissane on October 10, 2025 at 1:00 pm
We were on the ground in Barcelona speaking to biotech companies, university technology transfer offices, and top pharma firms about their experience at BIOSPAIN and their progress towards securing partnerships. The post Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next step appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trialon October 10, 2025 at 10:36 am
Cabaletta Bio’s CAR-T cell therapy successfully eliminated the overreactive B cells of two patients with an autoimmune disease, even without any preconditioning chemotherapy, pleasing investors and analysts alike and providing hope of less toxic autoimmune treatments.
- Amid the dip, biotech execs share silver linings in a tumultuous environmenton October 10, 2025 at 10:33 am
In an Oct. 9 discussion about innovation, resilience and the road ahead, panelists explored how federal uncertainty has affected the biotech sector, while also highlighting potential silver linings in the current environment.
- BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influenceon October 10, 2025 at 8:18 am
The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a preclinical CD19 autoimmune program.
- Contraline’s ADAM in the clinic: towards a new era of male contraception?by Dylan Kissane on October 10, 2025 at 8:00 am
In this week's podcast we talked with Kevin Eisenfrats, CEO of Contraline, about contraception, male contraception. The post Contraline’s ADAM in the clinic: towards a new era of male contraception? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Shuttle Pharma launches into AI drug discovery space via $10M acquisitionon October 10, 2025 at 5:58 am
Shuttle Pharmaceuticals has rocketed into the AI-driven drug discovery space via the planned $10 million acquisition of Molecule.ai.
- Inflammation biotech Evommune eyes IPO to fund further dermatitis trialson October 10, 2025 at 5:07 am
It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by the public markets.
- Regeneron amplifies CHORD progression, sharing updated data on hearing loss gene therapyon October 10, 2025 at 4:56 am
Regeneron has posted updated clinical data on DB-OTO, providing more evidence of the gene therapy’s potential to treat a rare genetic form of deafness as it plans for a potential FDA filing later this year.
- AstraZeneca: Building a transparent pipeline from the ground upon October 10, 2025 at 4:52 am
Transparency is often a word pharma companies like to use, but in practice, they rarely live up to the ideal. AstraZeneca is trying to be truly transparent with its new Discovery Centre.
- Fortrea and Belite Bio talk innovation in ophthalmology trialson October 9, 2025 at 3:02 pm
Patient-centric strategies and global partnerships drive progress in eye disease research
- 2 ex-Moderna leaders unveil $325M inaugural VC fund for platform biotechson October 9, 2025 at 1:44 pm
Two ex-Moderna leaders have hit a milestone in their new endeavor, closing a $325 million inaugural fund for their biotech venture capital firm called Ascenta.
- Chutes & Ladders—Former CBER chief Peter Marks leaps to Lillyby , on October 9, 2025 at 1:41 pm
Peter Marks, M.D., Ph.D., the former head of the FDA’s Center for Biologics Evaluation and Research (CBER), has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Marks served as CBER chief for nearly a decade until butting heads with Department of Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.
- Are European biotech VCs under pressure to scale? Time to get pragmatic by Jules Adam on October 9, 2025 at 1:00 pm
As Asabys Partners has rolled Aliath Bioventures into its platform, it's worth asking if European biotech VCs are under pressure to scale. The post Are European biotech VCs under pressure to scale? Time to get pragmatic appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Expedition resupplies for phase 2 COPD voyage with $165M series Aon October 9, 2025 at 9:55 am
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstructive pulmonary disease.
- Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer teston October 9, 2025 at 9:39 am
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer.
- AviadoBio secures option to rare eye disease gene therapy that could bring Chinese biotech $413Mon October 9, 2025 at 7:53 am
England's AviadoBio is looking to China as a potential source of additional gene therapies, securing an option to a $413 million biobucks deal that could deliver a rare eye disease candidate.
- Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospecton October 9, 2025 at 7:42 am
Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market.
- CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drugon October 9, 2025 at 5:34 am
Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate Lisata’s tumor drug.
- Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Riskon October 8, 2025 at 3:45 pm
AAIC 2025 spotlights inflammation in Alzheimer’s; InMed’s INM-901 reduces key biomarkers linked to disease progression
- Top biotech deals in September 2025 by Roohi Mariam Peter on October 8, 2025 at 8:00 am
Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals were signed. The post Top biotech deals in September 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Learn strategies to address PFAS challenges facing the medical device industry.on October 7, 2025 at 2:35 pm
PFAS's environmental persistence and health risks are prompting regulations impacting medical devices. Discover key insights and solutions from the experts at Battelle.
- Six companies leading the mRNA revolution in biotechnologyby Roohi Mariam Peter on October 7, 2025 at 1:00 pm
Here are six mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials. The post Six companies leading the mRNA revolution in biotechnology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain by Jules Adam on October 7, 2025 at 8:19 am
Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS). The post AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- The biggest biotech funding rounds in September 2025by Willow Shah-Neville on October 3, 2025 at 1:00 pm
uniQure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds overall in September 2025. The post The biggest biotech funding rounds in September 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy playby Dylan Kissane on October 3, 2025 at 8:00 am
This week, we discussed funding with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B round. The post Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Merck backs out of Britain: is the U.K. struggling to retain its life sciences sector? by Roohi Mariam Peter on October 1, 2025 at 1:19 pm
Merck’s decision to back out of its $1 billion expansion comes as U.K. investments in life sciences declines. The post Merck backs out of Britain: is the U.K. struggling to retain its life sciences sector? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Asthma study suggests lung scarring may be reversible by Jules Adam on September 30, 2025 at 11:01 pm
Find out about this new study that suggest that the lung scarring that severe asthma can cause could be reversible. The post Asthma study suggests lung scarring may be reversible appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- CRISPR technology’s next wave: Ten companies to watch in 2025 by Jules Adam on September 30, 2025 at 1:00 pm
Driven by CASGEVY's success, the CRISPR field is experiencing substantial growth with a new wave of companies. The post CRISPR technology’s next wave: Ten companies to watch in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Protecting Your Drug Patent in Global Markets: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 27, 2025 at 9:19 am
Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source
- Drafting Drug Patent Applications for Biologic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 11:45 am
The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source
- Successfully Patenting Drug Combinations: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 9:57 am
Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source
- Effective Strategies for Generic Drug Price Settingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 25, 2025 at 9:17 am
The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source
- Optimizing the Generic Drug Supply Chain: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 11:56 pm
Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source
- FDA Updates: What Do the Latest Changes Mean for Generic Drug Approval?by Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 8:55 pm
Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source
- Regulatory Challenges in the Latin American Generic Drug Marketby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 4:10 pm
Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source
- Analyzing the cost-effectiveness of biosimilars in different healthcare systemsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 23, 2025 at 11:27 am
The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source
- How to Achieve High-Quality Standards in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 20, 2025 at 11:21 am
Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source
- The Role of Quality Assurance in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 19, 2025 at 11:07 am
The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source
- DrugChatter: Can lurbinectedin treat ovarian cancer?by DrugChatter on February 19, 2025 at 6:44 am
Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source
- Regulatory considerations for biosimilar clinical efficacy trialsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 3:27 pm
Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source
- The basics of drug patent searchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 10:38 am
Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source
- Navigating the Generic Drug Approval Process: A Comprehensive Guideby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 17, 2025 at 10:33 am
Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source
- Strategies for successful biosimilar-to-biosimilar switchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 16, 2025 at 4:04 pm
The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source
- Study Reveals Key Predictors of Early Patent Challenges for FDA-Approved Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 14, 2025 at 11:40 am
The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source
- The Role of Partnerships in Generic Drug Developmentby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 13, 2025 at 9:12 am
Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source
- DrugChatter: Does fish oil interact with vascepa?by DrugChatter on February 12, 2025 at 9:10 pm
Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source
- How to Manage Generic Drug Development Timelines: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 12, 2025 at 9:10 am
The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source
- DrugChatter: How does lipitor affect white wine?by DrugChatter on February 11, 2025 at 4:56 pm
The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source
- Fierce Biotech Fundraising Tracker '25: Arthrosi adds $153M; Expedition gears up with $165Mby , , on December 23, 2024 at 12:22 pm
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
- Fierce Biotech Layoff Tracker 2025: Ascidian Tx trims team; Ferring plots 500 layoffsby , on December 23, 2024 at 11:52 am
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.